CTLA4 and combined immunodeficiency: Group 2 (Abatacept) included 12 girls and 5 boys whose median age was 10 (5–17) years, and the PID/genetic defects distribution was as follows: AT (ATM) (8/17), CTLA4 deficiency (CTLA4) (4/17), LRBA deficiency (LRBA) (2/17), NFkB1/2 deficiency (NFkB1/2) (2/17), and CID without genetic defect (1/17).